title: Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform.
abstract: OBJECTIVE
  To evaluate potential protein markers for oxaliplatin-based first-line chemotherapy of metastatic gastric cancer (MGC), we have used proteomic analysis to compare the difference of serum proteomic spectra between responsive and non-responsive MGC patients.
  
  
  METHODS
  Serum samples were collected before chemotherapy.Surface-enhanced laser desorption/ionisation time of-flight mass spectrometry (SELDI-TOF-MS) proteinchip array technology was applied to compare the differences of serous protein spectra between the twenty responsive patients and another fourteen non responsive patients. Cross validation was applied to identify the proper markers for an accurate judgment of prognosis.
  
  
  RESULTS
  Fifty proteins were picked out for significantly increased or decreased expression(p<0.05, Student t-test). Among them, sixteen protein masses with 1081, 1267, 2941, 2985, 3148, 3165,3199, 3219, 3249, 3281, 4182, 4390, 4482, 4509,4533 and 5001 m/z were chosen as components of the best proteomic biomarker pattern for judgment of chemotherapy prognosis in MGC patients, achieving a sensitivity of 95% (19/20) and a specificity of 78.6%(11/14), respectively.
  
  
  CONCLUSIONS
  SELDI-TOF-MS screens out the specific protein markers that help oncologists with judging the prognosis of oxaliplatin in combination with fluoropyrimidine, thus orientating first-line palliative chemotherapy for MGC patients.
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Yu
authors.forename: Jie-Kai
authors.initials: JK
authors.lastname: Yu
authors.forename: Xue-Feng
authors.initials: XF
authors.lastname: Fang
authors.forename: Ying
authors.initials: Y
authors.lastname: Yuan
authors.forename: Hong
authors.initials: H
authors.lastname: Shen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D018579:Patient Selection; D057285:Precision Medicine; D011237:Predictive Value of Tests; D040081:Protein Array Analysis; D040901:Proteomics / Q000379:methods*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil